Treatments for recurrent hypopharyngeal cancer

Recurrent hypopharyngeal cancer means that the cancer has come back after it has been treated. The following are treatment options for recurrent hypopharyngeal cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.

Treatment options depend on where the cancer comes back (recurs), the size of the cancer, which treatments you received for the original cancer and your overall health.

Surgery

You may be offered surgery for resectable hypopharyngeal tumours that come back if the original cancer was treated with minimally invasive surgery, radiation or chemoradiation. Chemoradiation combines radiation therapy with chemotherapy. The 2 treatments are given during the same time period. The goal of surgery is to remove the recurrent tumour.

Radiation therapy

You may be offered radiation therapy for recurrent hypopharyngeal cancer. It may be used as the main treatment if radiation wasn’t used to treat the original cancer. In some cases, it may be given again (called re-irradiation) even if it was used to treat the original cancer. Radiation therapy may be given alone, as part of chemoradiation or with a targeted therapy drug.

Chemotherapy

You may be offered chemotherapy for recurrent hypopharyngeal cancer. Cancer that can’t be removed by surgery or comes back in distant places is often treated with chemotherapy. The following drugs may be used alone or in combination:

  • cisplatin
  • carboplatin
  • fluorouracil (also called 5-fluorouracil or 5-FU)
  • methotrexate
  • paclitaxel
  • docetaxel
  • bleomycin
  • ifosfamide (Ifex)

Chemoradiation

You may be offered chemoradiation for recurrent hypopharyngeal cancer. In chemoradiation, chemotherapy is given during the same time period as radiation therapy. For recurrent hypopharyngeal cancer, cisplatin is usually the chemotherapy drug given along with radiation to the tumour and lymph nodes on both sides of the neck.

Targeted therapy

You may be offered targeted therapy for recurrent hypopharyngeal cancer. It may be given alone or along with radiation therapy or chemotherapy. Cetuximab (Erbitux) is he most common targeted therapy drug used to treat hypopharyngeal cancer.

Immunotherapy

You may be offered immunotherapy for recurrent hypopharyngeal cancer. Immunotherapy helps to strengthen or restore the immune system's ability to fight cancer.

Pembrolizumab (Keytruda) may be used as a first-line therapy to treat unresectable recurrent hypopharyngeal cancer. It may be given with or without chemotherapy.

Nivolumab (Opdivo) may be used to treat recurrent hypopharyngeal cancer that has stopped responding to chemotherapy with platinum drugs such as cisplatin or carboplatin.

If you can’t have or don’t want cancer treatment

You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don’t work anymore, they’re not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don’t want cancer treatment.

Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.

Clinical trials

Talk to your doctor about clinical trials open to people with hypopharyngeal cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • American Cancer Society. Treating Laryngeal and Hypopharyngeal Cancer. 2021.
  • PDQ® Adult Treatment Editorial Board. Hypopharyngeal Cancer Treatment (Adult) (PDQ®) – Health Professional. Bethesda, MD: National Cancer Institute; 2019: https://www.cancer.gov/.
  • National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer Version 2.2023 . 2023: https://www.nccn.org/guidelines/category_1.
  • Machiels JP, Leemans CR, & Golusinski W. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practices guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020: 31(11): 146201475.
  • Mendenhall WM, Dziegielewski PT, Dunn LA. Cancer of the larynx and hypopharynx. DeVita VT Jr, Lawrence TS, Rosenberg S. eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, chapter 25, https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society